Recently, analyses on inhibitor development according to concentrate in previously untreated patients (PUPs) from two national cohort studies have been published. A similar analysis has been performed on the first 4 years of data collection of the European Haemophilia Safety Surveillance System (EUHASS) project.
Together with the initial report from the RODIN study published in 2013, these publications provide data on a very considerable number of patients, almost exclusively originating from Europe.